SZIRAK: In an unassuming house in rolling hills east of the Hungarian capital, a small family firm is helping oil the wheels of the world’s big pharmaceutical companies on the path to a coronavirus vaccine.
Biologist Noemi Lukacs, 71, retired to Szirak, her birth village, to establish English & Scientific Consulting (SciCons) and manufacture a genetic sensor so sensitive that a few grams can supply the entire global industry for a year.
“We produce monoclonal antibodies,” Lukacs told Reuters in the single-storey house where she was born, now partly converted into a world-class laboratory. The white powder ships worldwide from here, micrograms at a time.
“These antibodies recognise double-stranded RNA (dsRNA),” she explained. DsRNA is a byproduct of viruses replicating, so its presence signals the presence of a live virus, long useful in virus-related research.
More importantly, dsRNA is also a byproduct of the process used by U.S. giant Pfizer and Germany’s BioNTech to create their experimental COVID-19 vaccine which is more than 90% effective according to initial trial results last week.
And because dsRNA can be harmful to human cells, it has to be filtered out from any vaccine to be used in humans. Several filtering methods exist, but the most widely used way to do quality control is to expose the vaccine to Lukacs’ antibodies.
Not only will the antibodies show if there is any dsRNA in the vaccine, they will also tell researchers how much of it is present. Only once completely freed from dsRNA can the vaccine be administered.
The result: a line of big pharma representatives outside her door.
The small company is growing rapidly, yet its revenue was only 124 million forints (just over $400,000) last year, with profits at 52 million forints. That feeds five employees and even leaves some for local charity projects in Szirak.
To Lukacs, that is just fine. The success of the RNA field, long frowned upon, is vindication enough.
DOG IN THE RACE
The former university professor followed the race to the vaccine closely and rooted especially for the contestants who look set to come first: those using modified RNA to train cells of the human body to recognise and kill the coronavirus. The RNA was her dog in the race.
The modified RNA, or mRNA, methodology is a whole new group of drugs, with the COVID vaccine the first product likely to get regulatory approval and go into mass production. But more applications are expected, which has Lukacs overjoyed.
“Once you get into the RNA field, it is an extremely exciting area,” she said, recalling decades of struggles when the rest of the scientific community did not share her excitement.
Or most of the rest, that is. Another Hungarian woman, Katalin Kariko, working across the Atlantic, patented the method that enables the use of RNA and promises to free the world not only of the coronavirus but scores of other diseases.
In the process, Kariko – now the Vice President of Germany’s BioNTech, which was first alongside U.S. giant Pfizer to break through with a vaccine earlier this month – became an early SciCons customer.
The COVID breakthrough and other RNA uses may necessitate more use of Lukacs’s antibodies as well, but they do not anticipate much of a boon.
“We would be happy to sell more of it,” said Johanna Symmons, her daughter and the small company’s chief executive. “We probably will too. But it’s not like we’ll get silly rich.”
Being part of the solution reaps its own rewards.
“We have cooperated with most vaccine manufacturers, and certainly almost all of the ones using the mRNA method,” she said with a hint of pride. “We have been a small screw in this large machine.”
KATHMANDU: A team from Seven Summit Treks ‘First Arab Ama Dablam Expedition’ comprising Qatari climber Fahad Badar, Sherief Elabd from Eygpt and Nadhira Al Harthy from Oman have attempted Mt Ama Dablam (6812 m) on January 14. The winter ascent to Ama dablam consisted of at least 14 climbers w Read More...
WILMINGTON, DELAWARE: President-elect Joe Biden unveiled a $1.9 trillion coronavirus plan Thursday to end “a crisis of deep human suffering” by speeding up vaccines and pumping out financial help to those struggling with the pandemic’s prolonged economic fallout. Called the “American Read More...
KATHMANDU, JANUARY 14 Mobile data users in the country are increasingly abandoning Ncell and subscribing state-owned Nepal Telecom. At least that is what the data compiled by Nepal Telecommunications Authority reveals. According to the Management Information System of NTA, 60 per cent of the t Read More...
KATHMANDU, JANUARY 14 Nepal Communist Party (NCP) led by Pushpa Kamal Dahal and Madhav Kumar Nepal held its Standing Committee meeting and discussed ways to effectively carry out its protest programme against dissolution of the House of Representatives. NCP (Dahal-Nepal) Spokesperson Naryan Ka Read More...
KATHMANDU, JANUARY 14 Nepal Police destroyed cannabis and opium plants cultivated in a large swathe of land across the country in the fiscal year 2019-20, according to an annual report recently released by the Ministry of Home Affairs. According to the report, cannabis plants being cultivated Read More...
KATHMANDU, JANUARY 14 Member countries in the World Health Organisation South-East Asia Region are gearing up for massive vaccination campaigns in a bid to end the COVID-19 pandemic. The WHO South-East Asia Region has 11 member countries — Bangladesh, Bhutan, Democratic People’s Republic o Read More...
DAMAULI, JANUARY 14 Janata Samaj Party-Nepal Federal Council Chairperson Baburam Bhattarai has stressed the need of a decisive struggle to protect democracy and the constitution. Accusing Prime Minister KP Sharma Oli of putting the constitution and democracy at risk by dissolving the Parliamen Read More...
BARA, JANUARY 14 The locals have protested a survey of the East-West Railway in Bara. The locals were up in arms after a survey was done affecting the main settlement in the bazaar area of Nijgadh Municipality. According to the survey team Incharge Suraj Poudel, the locals impeded the d Read More...